

Eleftherios Michailidis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7136823/publications.pdf>

Version: 2024-02-01

51
papers

10,746
citations

159525

30
h-index

189801

50
g-index

64
all docs

64
docs citations

64
times ranked

20015
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,749
3	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.	13.7	1,742
4	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020, 9, .	2.8	1,239
5	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	503
6	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	379
7	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	5.6	357
8	Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. <i>Cell</i> , 2021, 184, 120-132.e14.	13.5	328
9	CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. <i>Scientific Reports</i> , 2015, 5, 10833.	1.6	245
10	LY6E impairs coronavirus fusion and confers immune control of viral disease. <i>Nature Microbiology</i> , 2020, 5, 1330-1339.	5.9	170
11	Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	130
12	Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. <i>Cell Host and Microbe</i> , 2021, 29, 267-280.e5.	5.1	127
13	Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor. <i>Journal of Biological Chemistry</i> , 2009, 284, 35681-35691.	1.6	117
14	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	3.3	110
15	The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes. <i>PLoS Pathogens</i> , 2013, 9, e1003125.	2.1	96
16	4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms. <i>Journal of Biological Chemistry</i> , 2014, 289, 24533-24548.	1.6	80
17	Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. <i>Journal of Hepatology</i> , 2016, 65, 334-343.	1.8	73
18	Structural basis of HIV inhibition by translocation-defective RT inhibitor 4â€²-ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9274-9279.	3.3	73

#	ARTICLE	IF	CITATIONS
19	Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. <i>Viruses</i> , 2010, 2, 606-638.	1.5	70
20	Inherited IL-18BP deficiency in human fulminant viral hepatitis. <i>Journal of Experimental Medicine</i> , 2019, 216, 1777-1790.	4.2	70
21	Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. <i>Journal of Hepatology</i> , 2017, 66, 288-296.	1.8	65
22	A robust cell culture system supporting the complete life cycle of hepatitis B virus. <i>Scientific Reports</i> , 2017, 7, 16616.	1.6	61
23	Characterization of Novel Splice Variants of Zinc Finger Antiviral Protein (ZAP). <i>Journal of Virology</i> , 2019, 93, .	1.5	61
24	Biochemical Mechanism of HIV-1 Resistance to Rilpivirine. <i>Journal of Biological Chemistry</i> , 2012, 287, 38110-38123.	1.6	59
25	Replication and single-cycle delivery of SARS-CoV-2 replicons. <i>Science</i> , 2021, 374, 1099-1106.	6.0	49
26	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. <i>Cell Host and Microbe</i> , 2020, 28, 335-349.e6.	5.1	48
27	Expansion, in vivo ex vivo cycling, and genetic manipulation of primary human hepatocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1678-1688.	3.3	41
28	Antiviral therapies: Focus on hepatitis B reverse transcriptase. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 1060-1071.	1.2	40
29	Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. <i>Retrovirology</i> , 2013, 10, 65.	0.9	36
30	Effects of Substitutions at the 4' and 2' Positions on the Bioactivity of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6254-6264.	1.4	35
31	Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2048-2061.	1.4	31
32	Hepatitis B virus induces RNR-R2 expression via DNA damage response activation. <i>Journal of Hepatology</i> , 2015, 63, 789-796.	1.8	30
33	K70Q Adds High-Level Tenofovir Resistance to the Q151M Complex HIV Reverse Transcriptase through the Enhanced Discrimination Mechanism. <i>PLoS ONE</i> , 2011, 6, e16242.	1.1	29
34	Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. <i>Cancer Discovery</i> , 2021, 11, 2544-2563.	7.7	27
35	SAMHD1 Has Differential Impact on the Efficacies of HIV Nucleoside Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4915-4919.	1.4	25
36	Liver-expressed <i>Cd302</i> and <i>Cr11</i> limit hepatitis C virus cross-species transmission to mice. <i>Science Advances</i> , 2020, 6, .	4.7	23

#	ARTICLE	IF	CITATIONS
37	Evaluation of Combinations of 4-ethynyl-2-fluoro-2-deoxyadenosine with Clinically Used Antiretroviral Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4554-4558.	1.4	21
38	Inhibitors of Foot and Mouth Disease Virus Targeting a Novel Pocket of the RNA-Dependent RNA Polymerase. <i>PLoS ONE</i> , 2010, 5, e15049.	1.1	21
39	Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3482-3492.	1.4	20
40	3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	19
41	Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 189-198.	1.8	19
42	HIV nucleoside reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114554.	2.6	19
43	Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. <i>Nucleic Acids Research</i> , 2012, 40, 345-359.	6.5	14
44	Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. <i>Viruses</i> , 2019, 11, 1039.	1.5	14
45	Development of Human Immunodeficiency Virus Type 1 Resistance to 4-ethynyl-2-fluoro-2-deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0116721.	1.4	10
46	HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors. <i>Journal of Biological Chemistry</i> , 2012, 287, 29988-29999.	1.6	9
47	Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122. <i>Journal of Hepatology</i> , 2016, 64, 257-259.	1.8	9
48	DRUL for school: Opening Pre-K with safe, simple, sensitive saliva testing for SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0252949.	1.1	5
49	Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots. <i>International Journal of Current Chemistry</i> , 2011, 2, 253-260.	1.0	2
50	RNR-R2 Upregulation by a Short Non-Coding Viral Transcript. <i>Biomolecules</i> , 2021, 11, 1822.	1.8	1
51	Primary human hepatocyte gene editing: Prometheus™ chains are loosening. <i>Molecular Therapy</i> , 2021, 29, 1666-1667.	3.7	0